<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121302</url>
  </required_header>
  <id_info>
    <org_study_id>D3030C00001</org_study_id>
    <nct_id>NCT01121302</nct_id>
  </id_info>
  <brief_title>Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects</brief_title>
  <official_title>A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability &amp; PK of Single Ascending Dose (Part 1) &amp; an Open-label Assessment of Effect of Food on the PK (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The main purpose of this study is to assess the safety and tolerability of AZD5213 after
           single oral doses.

        2. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how
           the study drug enters and leaves your body and how your body acts on the study drug) of
           AZD5213 in your blood and urine.

      One group of subjects will be studied to see how food affects the pharmacokinetics (PK) of
      AZD5213 in the blood and urine. They will receive AZD5213 once after fasting overnight and
      then return to the clinic to receive AZD5213 after eating a high fat breakfast.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, vital signs, physical (including neurological) examinations, clinical laboratory variables, electrocardiograms, telemetry, sleep diary (temporal and qualitative aspects), and the Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>AE will be collected from admission on Day -1 until follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 : Investigate single-dose PK and dose proportionality of orally-administered AZD5213</measure>
    <time_frame>Frequent timepoints within 48 hours of single dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Investigate the potential effect of food on AZD5213 PK after administration of AZD5213 as an oral solution</measure>
    <time_frame>Frequent timepoints after volunteer consumes a high fat, high calorie breakfast, per FDA guidelines.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Tolerability</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalating</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5213</intervention_name>
    <description>0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suitable veins for cannulation or repeated venipuncture.

          -  Male healthy volunteers should be willing to use barrier contraception during sexual
             intercourse, ie condoms, even if partner is using contraceptive method, from the first
             day of dosing until 3 months after the last dosing with AZD5213.

          -  Body weight of ≥50 to ≤100 Kg and Body Mass Index (BMI) ≥18 to ≤30 kg/m2.

        Exclusion Criteria:

          -  History and presence of any clinically significant disease or disorder such as
             cardiovascular, pulmonary, renal, hepatic, neurological, gastorintestinal and
             psychiatric/mental disorders.

          -  History or presence of gastrointestinal (including irritable bowel disease), hepatic
             or renal disease or any other condition known to interfere with absorption,
             distribution, metabolism, or excretion of drugs. Surgery on gastrointestinal tract.

          -  History of previous or ongoing psychiatric disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1312&amp;filename=D3030C00001_Clinical_Study_Report_Synopsis.pdf</url>
    <description>D3030C00001 Clinical Study Report Synopsis</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD5213</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

